<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087879</url>
  </required_header>
  <id_info>
    <org_study_id>191/2006</org_study_id>
    <nct_id>NCT01087879</nct_id>
  </id_info>
  <brief_title>The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism</brief_title>
  <official_title>The Impact of Different Administration Routes of Hormonal Contraceptives on Androgen Synthesis, Glucose Metabolism and Inflammation. A Prospective Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of different administration routes of hormonal contraceptives on androgen
      secretion, glucose metabolism and inflammation. A prospective randomized trial.

      The investigators assume, that transdermal or transvaginal hormonal contraception would have
      less effects on androgen levels, glucose metabolism and inflammatory markers than oral
      contraceptives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      45 patients are recruited in the study. Each study group will consist of 15 women (aged 20-35
      years) receiving oral, transdermal or transvaginal hormonal contraception continuously for 9
      weeks. The subjects should have at least 2 months wash out period from all hormonal
      medication prior to the study.

      The measurements for serum sampling and OGTT will be performed before and after 9 weeks of
      medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Androgen secretion</measure>
    <time_frame>0, 5, 9, 10 weeks</time_frame>
    <description>Analysis of androstenedione, testosterone and DHEAS from fasting serum samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein secretion from liver</measure>
    <time_frame>0, 5, 9, 10 weeks</time_frame>
    <description>Analysis of SHBG and high sensitivy CRP from fasting serum samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>0, (5), 9, (10) weeks</time_frame>
    <description>Oral glucose tolerance test at 0 and 9 weeks. Fasting glucose, insulin and c-peptid at 5 and 10 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Oral contraceptive pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9 weeks treatment with contraceptive pill.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contraception vaginal ring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9 weeks treatment with vaginal ring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal contraceptive patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9 weeks treatment with a transdermal contraceptive patch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel-Ethinyl Estradiol contraceptive pill</intervention_name>
    <description>150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.</description>
    <arm_group_label>Oral contraceptive pill</arm_group_label>
    <other_name>Mercilon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel-Ethinyl Estradiol vaginal ring</intervention_name>
    <description>Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.</description>
    <arm_group_label>Contraception vaginal ring</arm_group_label>
    <other_name>NuvaRing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norelgestromin-Ethinyl Estradiol contraceptive patch</intervention_name>
    <description>A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.</description>
    <arm_group_label>Transdermal contraceptive patch</arm_group_label>
    <other_name>Evra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women aged from 20 to 35 years

          -  regular menstruation

          -  no use of hormonal contraception or two months wash-out period

          -  no contraindications for using hormonal contraception

        Exclusion Criteria:

          -  irregular menstruation

          -  smoking

          -  alcohol addiction

          -  pregnancy or nursing

          -  hypersensitivity to any components of the products

          -  headaches with focal neurological symptoms

          -  serious or multiple risk factors for artery disease

          -  undiagnosed abnormal genital bleeding

          -  impaired glucose tolerance or DM-T2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha S. Tapanainen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Dept Ob-Gyn, University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terhi T. Piltonen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept Ob-Gyn, University of Oulu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna M. Puurunen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Ob-Gyn, Univeristy of Oulu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynaecology, University of Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Terhi Piltonen/M.D., Ph.D.</name_title>
    <organization>Dept Ob-Gyn, University of Oulu</organization>
  </responsible_party>
  <keyword>oral glucose tolerance test</keyword>
  <keyword>hormonal contraception</keyword>
  <keyword>androgens</keyword>
  <keyword>crp</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Norelgestromin</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

